ACELYRIN, INC., a Westlake-funded late-stage clinical biopharma company, will use the financing to accelerate Phase 3 development of izokibep, a unique IL-17A inhibitor to treat inflammatory diseases including psoriatic arthritis and axial spondyloarthritis.
Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, announced the close of a $220 million Series B financing round. Proceeds from the financing will help the company expand its programmable cell therapy research activities and grow its pipeline of therapeutic candidates for solid tumor malignancies across a range of cancer indications.
3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, announced its launch from stealth backed by $40 million Series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. As part of its launch, 3T announced it has exclusively in-licensed from Stanford University a precise antibody-based peptide-HLA therapeutic discovery platform and development-stage MAGE-A3 T-cell receptor (TCR)-T assets to rapidly expand 3T’s therapeutic portfolio.
Three scientists from Westlake-founded companies have made this year’s Endpoints Top 20 Scientists Under 40 list. Meet Sharif Tabebordbar, Nick Goeden,
Westlake’s co-founding managing director, Beth Seidenberg, MD, was profiled in the cover story of this month’s edition of Pharmaceutical Executive.
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced it has closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company’s total financing raised to date to $213.5 million. Neuron23’s Series A and B investors – Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, and Surveyor Capital (a Citadel company) – also participated in the Series C financing round.
Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. Additional investors included the company’s founding investors Westlake Village BioPartners, Vida Ventures, and Gilead Sciences, with new investors RTW Investments, LP, CAM Capital, Insight Partners, HealthCor, LYFE Capital, Intellia Therapeutics, Argentum Peak, Hudson Bay Capital, and jVen Capital.
The Healthcare Businesswomen’s Association (HBA) announced Westlake’s Beth Seidenberg as the 2022 Woman of the Year. She was recognized for her significant contributions to healthcare and the advancement of women in the industry.
Westlake today announced the appointment of Mira Chaurushiya, Ph.D., to the position of senior partner. Dr. Chaurushiya will be a full investing partner at Westlake. She joins the firm from 5AM Ventures, where she spent more than six years growing and building next-generation life sciences companies.
Westlake-backed ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the closing of its hugely successful Series B round of financing.
